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Background:Weight loss limits cancer therapy, quality of life and survival. Common diagnostic criteria and a framework
for a classiﬁcation system for cancer cachexia were recently agreed upon by international consensus. Speciﬁc assess-
ment domains (stores, intake, catabolism and function) were proposed. The aim of this study is to validate this diagnostic
criteria (two groups: model 1) and examine a four-group (model 2) classiﬁcation system regarding these domains as well
as survival.
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Patients and methods: Data from an international patient sample with advanced cancer (N = 1070) were analysed. In
model 1, the diagnostic criteria for cancer cachexia [weight loss/body mass index (BMI)] were used. Model 2 classiﬁed
patients into four groups 0-III, according to weight loss/BMI as a framework for cachexia stages. The cachexia domains,
survival and sociodemographic/medical variables were compared across models.
Results: Eight hundred and sixty-one patients were included. Model 1 consisted of 399 cachectic and 462 non-cachectic
patients. Cachectic patients had signiﬁcantly higher levels of inﬂammation, lower nutritional intake and performance status
and shorter survival. In model 2, differences were not consistent; appetite loss did not differ between group III and IV, and
performance status not between group 0 and I. Survival was shorter in group II and III compared with other groups. By
adding other cachexia domains to the model, survival differences were demonstrated.
Conclusion: The diagnostic criteria based on weight loss and BMI distinguish between cachectic and non-cachectic
patients concerning all domains (intake, catabolism and function) and is associated with survival. In order to guide
cachexia treatment a four-group classiﬁcation model needs additional domains to discriminate between cachexia
stages.
Key words: cancer, cachexia, classiﬁcation, validation
introduction
Cachexia affects 60%–80% of all advanced cancer patients [1],
and its consequences are devastating as it decreases physical
function and quality of life, and shortens survival [2]. Cancer
cachexia is a complex condition that is not yet fully understood
and there is no standard treatment available [3].
Traditionally, patients with a weight loss of more than 5% of
pre-illness stable weight have been considered to have some
degree of cachexia, but other cut-offs have also been used (e.g.
>10%, 2%) [4]. A three-factor model incorporating weight loss
(≥10%), low food intake (1500 kcal/day) and systemic inﬂam-
mation (C-reactive protein ≥10 mg/l) was tested by Fearon et al.
in 170 advanced cancer patients [5]. In this study, all three
factors had to be applied in order to identify patients with both
adverse function and shortened survival.
Recently, an international panel of cachexia experts initiated a
formal consensus process to agree on a common deﬁnition and
a framework for the development of a new classiﬁcation system
for cancer cachexia [6]. Weight loss, body mass index (BMI)
and levels of muscle mass (sarcopenia) forms the basis of this
consensus deﬁnition. Additionally, information about anorexia
or reduced food intake, catabolic drive, muscle strength as well
as physical, social and psychological function were proposed as
important domains for a cancer cachexia classiﬁcation system. It
was furthermore agreed that cancer cachexia is to be considered
a trajectory and can be classiﬁed into the stages, pre-cachexia,
cachexia and refractory cachexia.
Staging of cancer cachexia is of importance in guiding treatment
decisions and inclusions into clinical trials. Both ends of the cancer
cachexia trajectory must be recognized. For instance treatments to
prevent or delay the development of cancer cachexia should be
initiated early in the trajectory, and thus a clear distinction of the
pre-cachexia is needed. In refractory cachexia where the tumour is
no longer responding to anticancer treatment and the life expect-
ancy is short, the primary focus should be symptom management
and general care according to end of life care guidelines.
These stages were not accurately deﬁned and how these
domains should be assessed and operationalized in a classiﬁca-
tion system remains unclear.
The overall aim of this study was to contribute to the develop-
ment of a new classiﬁcation system for cancer cachexia by
examining two classiﬁcation models based on information on
weight loss and BMI: (i) a two-group model validating the diag-
nostic criteria and (ii) a four-group model as a preliminary
framework for classifying cachexia into stages. The research
questions asked were as follows:
• Is a four-group model better than a two-group model in terms
of classifying patients into different stages of cachexia?
• How can factors representing the other key cancer cachexia
domains (intake, catabolism and function) contribute to the
classiﬁcation?
materials andmethods
patients and study design
Patients were recruited from an international multicentre study initiated by
the European Palliative Care Research Collaborative (EPCRC) [7]. A cross-
sectional data collection was conducted from October 2008 until December
2009 in palliative care in-and out-patient units, hospices and general oncol-
ogy and medical wards in several European countries (Norway, UK, Austria,
Germany, Switzerland, Italy, Canada and Australia). Patients were eligible if
they were aged ≥18 years and had an incurable metastatic or locally
advanced cancer diagnosis. Patients not able to complete assessments due to
physical or cognitive impairment or language problems were excluded. The
ethical authorities in all participating centres approved the study protocol,
and all patients gave their written informed consent.
data collection
Data were collected on touch-sensitive computers (HP Compaq TC4200
1200 tablet PCs made by Hewlett-Packard Development Company L.D.).
Details on the lay-out and speciﬁcations for the computerized assessment
have been presented by the EPCRC previously [8]. Data collection consisted
of two parts: one to be completed by the study coordinators and the other
part to be completed by the patients. A research assistant was available and
provided help as necessary. All data were entered by tapping directly on the
computer screen with an electronic pen.
assessments
Demographic information (age, gender, CRP and date of death), cancer
diagnosis (ICD-10), stage of disease (locally advanced versus metastatic),
performance status [9] and current oncological treatment (chemotherapy
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or not) was collected from the patients’ medical records by the study
coordinators.
Assessments of symptoms were performed using Edmonton Symptom
Assessment System (ESAS) [10] which includes nine numerical ratings
scales, scoring 0 (no problem) to 10 (worst possible problem), for the symp-
toms pain, tiredness, nausea, depression, anxiety, drowsiness, appetite,
feeling of well-being and shortness of breath.
Information about stature (weight, height), weight loss last 6 months (in
kg) and food intake past month (unchanged, changed or less than usual)
was provided by the patients using questions from the Scored Patient-
Generated Subjective Global Assessment (PG-SGA) [11].
two-group classiﬁcation model (model 1)
Patients were classiﬁed into two groups based on criteria from the inter-
national consensus [6]. Cachexia was weight loss >5% the past 6 months OR
any degree of weight loss >2% the last 6 months + BMI <20 kg/m2. Patients
above or below these cut-offs were grouped as: cachexia and no cachexia.
four-group classiﬁcation model (model 2)
As a preliminary framework for the staging system for cancer cachexia pro-
posed by the international consensus, a four-group model based on informa-
tion about weight loss and BMI was used in this analysis. In this model,
patients were classiﬁed into four weight loss groups (0–III) according to the
following criteria:
‘No cachexia (group 0)’: weight change (± 1 kg) or weight gain
‘Pre-cachexia (group I)’: weight loss >1 kg, but <5%
‘Cachexia (group II)’: weight loss >5% the last 6 months, or weight loss >2%
the last 6 month + BMI <20 kg/m2
‘Refractory cachexia (group III)’: weight loss >15% last 6 months + BMI <23
kg/m2 OR weight loss >20% last 6 months + BMI <27 kg/m2.
To further explore the consensus framework deﬁnition of pre-cachexia, a
weight loss model adding information from the cachexia domains catabol-
ism (CRP < or >10) and intake (appetite ESAS >3) was tested in terms of
survival (model 3).
statistical analysis
Model 1 (two groups) was tested by group-wise comparison of cachectic
versus non-cachectic patients with regards to items representing cachexia
domains as well as a range of demographic and medical information. For
continuous variables, an independent sample t-test was applied and a χ2 test
for categorical variables. In model 2 (four groups), comparisons using a one-
way analysis of variance (ANOVA), or a non-parametric equivalent
(Kruskal–Wallis test). Ninety-ﬁve percent conﬁdence intervals (95% CIs)
and P-values are presented.
To explore the relationship between cachexia domains and classiﬁcation
model (model 2), candidate items that differed between the groups in
the univariate analysis were entered into a multivariate logistic regression
by forced entry, and the no cachexia group (group 0) acted as the
reference group.
Univariate survival analysis was performed using the Kaplan–Meier
method and Cox regression (log-rank tests) to compare survival curves for
both models (model 1 and model 2) and for the pre-cachexia model (model
3). In this analysis, survival was deﬁned as time between date of clinical
assessment and death. Patients alive on 1 January 2011 were treated as
censored.
results
The EPCRC-CSA study included 1070 patients. Nineteen
patients were excluded either because they withdrew consent
(n = 4) or for technical failure (n = 15). Patients with missing
data on body weight (n = 86) and survival (n = 104) were also
excluded from the present study.
In total, 861 patients were subject to the ﬁnal analyses. Mean
age for all included patients was 62 years, 53% were males and
the mean performance status was 71.7. BMI was 24.2 kg/m2 and
the average weight loss last six months was 3.9 kg. The most
frequent diagnosis was cancer of the digestive organs (28%), fol-
lowed by breast cancer (17%) and cancer of the respiratory
organs (16%). The majority of patients suffered from metastatic
disease and more than half of the patients were hospitalized
(56%).
two-group classiﬁcation (model 1)
In model 1, 399 patients were classiﬁed as cachectic, while 462
patients were non-cachectic. The cachectic patients had a mean
BMI 23.0 kg/m2 and an average weight loss 9.8 kg, while the
non-cachectic had a mean BMI of 25.3 kg/m2 and an average
weight gain 1.1 kg. A separate analysis for criteria WL >5%
showed that by this criterion alone, 388 patients were classiﬁed
as cachectic. Ninety-nine patients were classiﬁed as cachectic by
the other diagnostic criteria WL >2% + BMI <20 kg/m2. There
was an overlap between these two criteria of 88 patients, leaving
only 11 that were not classiﬁed by both.
Characteristics for the two groups in model 1 are shown in
Table 1. In the cachectic patients, there were more males than
females (59% versus 41%; P < 0.01). In cachectic patients, the
most prevalent diagnosis was cancer of the digestive (30%) and
respiratory (18%) organs. There were more in-patients among
the cachectic patients (53% versus 47%, P < 0.001).
When comparing cachectic versus non-cachectic patients on
items representative of the key cachexia domains, higher levels
of CRP (44.8 versus 29.6 ml/g; P < 0.001) and appetite loss (3.9
versus 2.6; P < 0.001) and reduced food intake (58.6% versus
29.8%, P < 0.001) was observed for cachectic patients. Cachectic
patients had lower scores on KPS than the non-cachectic
patients (68.3 versus 74.5, P < 0.001).
four-group classiﬁcation (model 2)
As shown in Table 2, 147 patients were classiﬁed into pre-cach-
exia group (mean BMI 25.1 kg/m2 and WL 2.4 kg), 305 into
cachexia group (mean BMI 23.8 kg/m2 and WL 7.9 kg) and 86
patients into refractory cachexia group (mean BMI 19.9 kg/m2
and WL 16.8 kg). Three hundred twenty-three patients were
classiﬁed into no cachexia group (mean BMI 25.4 kg/m2 and
weight gain of 2.8 kg).
Serum concentrations of CRP (catabolism domain) were
similar in patients in the no cachexia and the pre-cachexia
group (30.3 and 29.3 ml/g, respectively) and were signiﬁcantly
higher in the cachexia group (40.6 ml/g) and the refractory
cachexia group (60.6 ml/g, P < 0.001).
The proportion of patients reporting a reduced food intake
(eating less than usual) was signiﬁcantly higher in pre-cachexia,
cachexia and refractory cachexia groups (48%, 56% and 47%)
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Table 1. Two-group classiﬁcation model (model 1)
Variables Groups in model 1 All patients in study
No cachexia: no weight loss
or low BMI
Cachexia: weight loss and
low BMI
P-value*
Number of patients 462 399 861
Age, mean (95% CI), years 62 (61–63) 62 (61–63) 0.850 62 (61–63)
Number of female within group (%) 235 (59) 166 (41) 0.07 401 (47)
Performance status
Karnofsky score (KPS), mean (95% CI) 74.5 (73.1–76.0) 68.3 (66.7–70.0) 0.001 71.7 (70.6–72.2)
Current medical situation, number (%)
In-patient 226 (47) 254 (53) <0.001 480 (56)
Outpatient 236 (62) 145 (38) <0.001 381 (44)
Diagnosis, number of yes within group (%)
Cancer of the head 13 (48) 14 (52) 27 (3)
Cancer of the digestive organs 123 (51) 119 (49) 242 (28)
Cancer of the respiratory organs 65 (48) 71 (52) 136 (16)
Malignant bone tumours 3 (100) 0 3 (0)
Skin cancer including malignant melanoma 18 (51) 17 (49) 35 (4)
Malignant connective and soft tissue tumours 17 (57) 13 (43) 30 (4)
Breast cancer 95 (65) 51 (35) 146 (17)
Gynaecological cancer 14 (64) 8 (36) 22 (3)
Cancer of male genital organs 46 (49) 47 (51) 93 (11)
Urinary cancer 25 (51) 24 (49) 49 (6)
Tumours of the CNS 11 (79) 3 (21) 14 (2)
Malignant endocrine tumours 1 (17) 5 (83) 6 (1)
Secondary an ill-deﬁned malignant tumours 13 (59) 9 (41) 22 (3)
Leukaemia and lymphomas 17 (55) 14 (45) 31 (4)
Multiple primary cancers 1 (25) (3 (75) 4 (1)
Current status of disease, number (%)
Advanced, non-metastatic 74 (58) 54 (42) 0.500 128 (15)
Metastatic 388 (53) 345 (47) 0.307 733 (85)
Current oncology treatment: number of yes within group (%)
Radiotherapy 86 (47) 98 (53) 0.034 184 (21)
Chemotherapy 247 (60) 166 (40) 0.001 413 (48)
Serum concentrations, mean (95% CI)a
CRP 29.6 (24.1–35.2) 44.8 (38.0–51.6) 0.001 36.9 (32.5–41.3)
Haemoglobin 12.1 (11.9–12.3) 11.6 (11.4–11.8) 0.001 11.9 (11.7–12.0)
Albumin 38.0 (37.3–38.6) 35.1 (34.4–35.7) 0.001 36.7 (36.1–37.1)
Food intake, number of yes within group (%)
Unchanged 275 (69) 125 (31) <0.001 400 (46)
More than usual 58 (64) 33 (36) 0.089 91 (11)
Less than usual 129 (35) 241 (65) <0.001 370 (43)
Symptoms, mean (95% CI)
Pain 1.9 (1.7–2.1) 2.4 (2.2–2.6) 0.001 2.1 (2.0–2.3)
Fatigue 3.3 (3.1–3.5) 4.1 (3.8–4.3) 0.001 3.6 (3.5–3.8)
Nausea 0.9 (0.8–1.1) 1.3 (1.1–1.6) 0.004 1.1 (1.0–1.3)
Depression 1.8 (1.6–2.0) 2.0 (1.8–2.3) 0.090 1.9 (1.7–2.1)
Anxiety 2.0 (1.8–2.2) 2.2 (1.9–2.4)) 0.200 2.1 (1.9–2.2)
Drowsiness 3.1 (2.9–3.3) 3.6 (3.4–3.8) 0.001 3.3 (3.2–3.5)
Appetite 2.6 (2.3–2.8) 3.9 (3.6–4.2) 0.001 3.2 (3.0–3.4)
Feeling of well-being 3.1 (2.9–3.3) 3.7 (3.5–3.9) 0.001 3.4 (3.2–3.5)
Shortness of breath 1.8 (1.6–2.0) 2.0 (1.8–2.3) 0.200 1.9 (1.7–2.1)
The table shows descriptive data on demographics, medical information and items representing key cachexia domains. Data are presented as means and
95% conﬁdence intervals (95% CIs) for continuous variables and as frequencies (n) and proportions (%) for categorical variables.
aCRP (n = 628), haemoglobin(n = 737), albumin (n = 671).
*In comparison to the two groups in the statistical analysis, an independent t-test was applied for continuous variables and for categorical variables, a
χ2 test.
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Table 2. Four-group classiﬁcation model (model 2) based on weight loss and BMI
Variables No cachexia
(Group 0)
Pre-cachexia
(Group I)
Cachexia
(Group II)
Refractory cachexia
(Group III)
P-value*
Number of patients 323 147 305 86
Age, mean (95% CI), years 61 (59.3–62.1) 64 (62.0–66.0) 63 (61.5–64.0) 60 (57.3–62.4) 0.010
Number of female within group (%) 168 (52) 70 (48) 126 (41) 37 (43) 0.030
Performance status
Karnofsky score (KPS), mean (95% CI) 74.7 (73.0–76.4) 75.0 (72.6–77.4) 68.2 (66.4–70.0) 66.8 (63.4–70.2) <0.001
Current medical situation, number of yes within group (%)
In-patient 158 (33) 78 (16) 184 (38) 60 (13) <0.001
Out-patient 165 (43) 69 (18) 121 (32) 26 (7) <0.001
Diagnosis, number of yes within group (%)
Cancer of the head 9 (33) 4 (15) 14 (52) 0
Cancer of the digestive organs 82 (34) 41 (17) 86 (36) 33 (14)
Cancer of the respiratory organs 45 (33) 19 (14) 60 (44) 12 (9)
Malignant bone tumours 2 (67) 1 (33) 0 0
Skin cancer including malignant melanoma 13 (37) 5 (14) 13 (37) 4 (11)
Malignant connective and soft tissue tumours 12 (40) 5 (17) 8 (27) 5 (17)
Breast cancer 71 (49) 27 (19) 40 (27) 8 (6)
Gynaecological cancer 11 (50) 4 (18) 3 (14) 4 (18)
Cancer of male genital organs 32 (34) 17 (18) 37 (40) 7 (8)
Urinary cancer 15 (31) 11 (22) 15 (31) 8 (16)
Tumours of the CNS 7 (50) 4 (29) 2 (14) 1 (7)
Malignant endocrine tumours 1 (17) 0 4 (67) 1 (17)
Secondary an ill-deﬁned malignant tumours 10 (46) 5 (28) 6 (27) 1 (5)
Leukaemia and lymphomas 12 (39) 4 (13) 14 (45) 1 (3)
Multiple primary cancers 1 (25) 0 2 (50) 1 (25)
Current status of disease, number of yes within group (%)
Advanced, non-metastatic 48 (38) 25 (19) 43 (34) 12 (9) <0.001
Metastatic 275 (37) 122 (17) 262 (36) 74 (10) <0.001
Current oncology treatment, number of yes within group (%)
Radiotherapy 57 (31) 34 (18) 76 (41) 17 (9) 0.036
Chemotherapy 167 (40) 79 (19) 139 (34) 28 (7) 0.074
Serum concentrations, mean (95% CI)a
CRP 30.3 (23.5–37.1) 29.3 (21.2–37.3) 40.6 (33.7–47.5) 60.6 (2.9–78.4) <0.001
Haemoglobin 12.1 (11.3–12.9) 12.0 (11.7–12.3) 11.7 (11.5–11.9) 11.0 (10.6–11.5) <0.001
Albumin 38.4 (37.6–39.2) 37.6 (36.7–38.6) 35.5 (34.8–36.2) 32.9 (31.4–34.4) <0.001
Food intake, number of yes within group (%)
Unchanged 206 (52) 68 (17) 106 (26) 20 (5) <0.001
More than usual 48 (53) 9 (10) 27 (30) 7 (8) 0.010
Less than usual 69 (19) 70 (19) 172 (47) 59 (16) <0.001
Symptoms, mean (95% CI)
Pain 2.1 (1.8–2.3) 1.6 (1.3–1.9) 2.4 (2.1–2.7) 2.5 (2.0–3.0) 0.003
Fatigue 3.2 (2.9–3.5) 3.4 (3.1–3.8) 3.9 (3.6–4.2) 4.6 (4.1–5.2) <0.001
Nausea 1.0 (0.8–1.2) 0.8 (0.6–1.1) 1.2 (1.0–1.5) 1.6 (1.1–2.2) 0.009
Depression 1.7 (1.5–1.9) 1.9 (1.5–2.3) 2.0 (1.8–2.3) 2.0 (1.5–2.5) 0.291
Anxiety 1.9 (1.7–2.1) 2.1 (1.7–2.5) 2.1 (1.8–2.4) 2.3 (1.8–2.9) 0.377
Drowsiness 3.0 (2.7–3.3) 3.2 (2.8–3.6) 3.6 (3.4–3.9) 3.7 (3.2–4.3) 0.006
Appetite 2.5 (2.2–2.8) 2.9 (2.4–3.4) 3.7 (3.3–4.0) 4.6 (3.9–5.2) <0.001
Feeling of well-being 3.1 (2.9–3.4) 3.1 (2.7–3.5) 3.7 (3.4–3.9) 3.9 (3.4–3.5) 0.003
Shortness of breath 1.7 (1.5–2.0) 1.9 (1.6–2.3) 2.1 (1.8–2.4) 1.8 (1.3–2.3) 0.325
The table shows descriptive data on demographics, medical information and items representing key cachexia domains. Data are presented as means and
95% conﬁdence intervals (95% CIs) for continuous variables and as frequencies (n) and proportions (%) for categorical variables.
aCRP (n = 628), hemoglobin (n = 737), albumin (n = 671).
*In comparison to the four groups in the statistical analysis, an analysis of variance (ANOVA) was applied for continuous variables and for categorical
variables, a Kruskal–Wallis test.
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compared with the no-cachexia group (22%; P < 0.001).
Compared with the no-cachexia group, mean scores on appetite
loss were signiﬁcantly higher in the pre-cachexia group (2.9),
cachexia group 2 (3.9) and the refractory cachexia group (4.6,
P < 0.001) than in the non-cachexia group.
The mean performance status (KPS) was signiﬁcantly lower
in the cachexia group (68.2) and the refractory cachexia group
(66.8) compared with scores in the no-cachexia and the pre-
cachexia group (75.0; P < 0.001).
Results from the multivariate logistic regression of candidate
items are presented in the appendix. Food intake (eating less
than usual) was a signiﬁcant item for all cachexia groups.
Appetite loss was a signiﬁcant item in terms of classifying re-
fractory cachexia (P < 0.05). CRP was not a signiﬁcant item for
the classiﬁcation into any of the three cachexia groups but a ten-
dency could be seen for the refractory cachexia group
(P < 0.065).
survival
The median overall survival for all patients was 207 days. In
model 1, the median survival for patients classiﬁed as cachectic
was shorter than for non-cachectic patients (139 versus 269
days; P < 0.001). There was no signiﬁcant survival difference,
between no cachexia and pre-cachexia (Figure 1).
A deﬁnition of pre-cachexia in a model adding additional
factors representing the cachexia domains (model 3) was tested.
By adding CRP (>10 ml/g) and appetite loss (ESAS >3) to the
<5% weight loss, the median survival was signiﬁcantly shorter
for patients with all three cachexia factors present compared
with those with only 0%–5% weight loss (143 versus 377 days;
P < 0.001).
discussion
This study shows that patients with cachexia are clearly distinct
from patients with no cachexia with regards to the key cachexia
domains (stores, nutrition, catabolism and function) and sur-
vival (model 1). This underlines the legitimacy of the established
diagnostic criteria for cancer cachexia based on weight loss/
BMI. However using weight loss/BMI alone is not sufﬁcient
when classifying cancer cachexia from pre-cachexia to refractory
cachexia (model 2).
In terms the cachexia characteristics, there appears to be little
distinction between the no cachexia and pre-cachexia; this
ﬁnding is also supported by the survival curves. Classiﬁcation of
pre-cachexia might be better based on additional items. A pos-
sible explanation for this is the inaccuracy of body weight mea-
sures and lack of information on sarcopenia. If only weight loss
is taken into account, some patients suffering from slight muscle
loss may be misclassiﬁed, because muscle loss can be masked
due to ﬂuid retention [12]. A measure of muscle loss by an
objective method such as computed tomography, dual-energy
X-ray, magnetic resonance imaging may be essential to speciﬁ-
cally diagnose pre-cachexia but these methods have so far not
been easily available in cancer clinics [13].
The refractory stage can be considered as cachexia with very
poor prognosis, as it is the cancer disease that deﬁnes this stage.
Unfortunately, there is no simple marker for tumour activity or
dynamics readily obtainable, which impedes an easily applicable
classiﬁcation in clinical practice.
Since the publication of the international consensus, two
other proposals for classiﬁcation of patients into cachexia stages
have been made. The ﬁrst, the Cachexia Score (CASCO) weights
and sums ﬁve different factors: body weight and lean body mass
loss; anorexia; inﬂammatory, immunological and metabolic dis-
turbances; physical performance and quality of life [14]. A valid-
ation of the score is awaited. A barrier for the use in clinics may
be the rarely available biochemical tests and missing cut-offs.
The clinical relevance of the consensus classiﬁcation has been
evaluated in 207 cancer patients by Vigano et al. [15]. In this
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Figure 1. Kaplan–Meyer survival plot for two-group (model 1) and four-group
(model 2) classiﬁcation models.
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pilot study, patients were classiﬁed into the three stages by two
independent researchers according to different combinations of
clinical criteria and biological measurements. The ﬁnal classiﬁ-
cation was mainly performed by subjective judgement, which is
not easily replicated. Similar to the present study, pre-cachexia
was not clearly distinctive but the other stages correlated with
differences in patient-reported outcomes and survival. Both of
these studies underline the importance of classiﬁcation to guide
treatment, but also the lack of simple indicators to classify
patients into the stages. In clinical practice, it is important to
have easily applicable measurements/assessments which allow
bedside diagnostics.
A recent publication highlighted the association of cancer
cachexia with symptoms, function, quality of life and survival in
a cluster analysis. Prevalence of cachexia varied highly according
to different deﬁnitions, which indicated once more the need for
a classiﬁcation with clear cut-offs [16].
limitations
A main limitation is that there was no measurement of muscle
mass available. In the nutrition domain, the simple answer of
‘eating less than usual’ was considered to be sufﬁciently precise
to measure decreased nutritional intake, even though this PG-
SGA question has not been validated for this comparison.
In the catabolism domain, CRP was used as the main item as
it is the most robust biomarker for cachexia inﬂammation [4].
CRP is indeed a marker for systemic inﬂammation, but is
neither speciﬁc for cancer, cachexia or for tumour activity as
it can be inﬂuenced by other factors such as infections. Due to
the inclusion criteria (computerized assessment), the population
of the study is younger and ﬁtter than the average cancer
population.
conclusion
In a large international cohort of advanced cancer patients,
weight loss and BMI clearly distinguish between non-cachectic
and cachectic patients both with regards to all the available
domains proposed by the international consensus and with sur-
vival. Exploring the possibility to classify patients into four
groups representing cachexia stages, using weight loss and BMI
only, provides some indication of a possible distinct refractory
cachexia group. The pre-cachexia stage might be better deﬁned
by additional factors representing the cachexia domain, for in-
stance CRP and appetite loss. A clear deﬁnition of pre-cachexia
is needed, especially because this group is the target of interven-
tion trials. The next steps in the validation of a cachexia classiﬁ-
cation should quantify additional factors and investigate the role
of muscle mass measurement.
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Table A1. Logistic regression for the four-group model (model 2)
Group I (pre-cachexia) Group II (cachexia) Group III (refractory
cachexia)
Domains B(SE) eB B(SE) eB B(SE) eB
Intercept −1.33 (0.86) 0.87 (0.65) −2.16* (1.07)
Catabolism
C-reactive protein mg/l −0.16 (0.20) 0.9 0.07 (0.17) 1.1 0.48 (0.26) 1.6
Nutrition
Food intake: eating less than usual 1.33** (0.46) 3.8 1.15** (0.34) 3.1 1.44* (0.59) 4.2
Nutition
ESAS appetite −0.02 (0.05) 1.0 0.07 (0.04) 1.1 0.12* (0.06) 1.1
Function
ESAS fatigue −0.01 (0.06) 1.0 0.05 (0.05) 1.1 0.12 (0.07) 0.9
ESAS feeling of well-being −0.12 (0.07) 0.9 −0.05 (0.05) 1.0 −0.14 (0.08) 1.0
Function
Karnofsky Performance Status 0.01 (0.01) 1.0 −0.02** (0.01) 1.0 −0.01 (0.01) 1.0
aGroup 0 (no cachexia) is the reference category.
*P < 0.05, **P < 0.01.
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